Liệu pháp miễn dịch phóng xạ với 131I-Rituximab ở một bệnh nhân mắc bệnh lymphoma tế bào B lớn lan tỏa tái phát sau điều trị bằng 90Y-Ibritumomab Tiuxetan

Jaffe ES. The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematol Am Soc Hematol Educ Program. 2009;523–31. Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:4587–94. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–2. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–6. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-hodgkin’s lymphoma. J Clin Oncol. 2006;24:4418–25. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-hodgkin’s lymphoma (NHL). Asia Pac J Clin Oncol. 2011;7:136–45. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–8. Han EJ, Lee SE, Kim SH, Sohn HS, Jung SE, Park G, et al. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (zevalin(R)) for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol. 2011;90:1075–82. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19:769–73. Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16:3998–4004. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, et al. Re-treatment with I-131 tositumomab in patients with non-hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985–93. Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945–53. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117:45–52.